These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3085136)

  • 41. Fluphenazine plasma levels and clinical response.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
    Asarnow RF; Marder SR; Mintz J; Van Putten T; Zimmerman KE
    Arch Gen Psychiatry; 1988 Sep; 45(9):822-6. PubMed ID: 3046554
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
    Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 45. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
    Viala A; Hou N; Ba B; Durand A; Dufour H; D'Agostino N; Berda C; Jørgensen A
    Psychopharmacology (Berl); 1984; 83(2):147-50. PubMed ID: 6146995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluphenazine pharmacokinetics and therapeutic response.
    Dysken MW; Javaid JI; Chang SS; Schaffer C; Shahid A; Davis JM
    Psychopharmacology (Berl); 1981; 73(3):205-10. PubMed ID: 6787637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia.
    McClelland HA; Farquharson RG; Leyburn P; Furness JA; Schiff AA
    Arch Gen Psychiatry; 1976 Dec; 33(12):1435-9. PubMed ID: 11760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weekly pimozide versus fluphenazine decanoate in schizophrenic out-and day-patients.
    McCreadie RG; McKane JP; Mackie M
    Br J Psychiatry; 1983 Jul; 143():97-8. PubMed ID: 6349740
    [No Abstract]   [Full Text] [Related]  

  • 49. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
    Glazer WM; Friedhoff LT; Marder SR; Brown WA
    Schizophr Res; 1992 Dec; 8(2):111-7. PubMed ID: 1457388
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
    Kane JM; Rifkin A; Woerner M; Reardon G; Sarantakos S; Schiebel D; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1983 Aug; 40(8):893-6. PubMed ID: 6347119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluphenazine decanoate: a clinical problem?
    Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
    Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluphenazine decanoate: plasma concentrations and clinical response [proceedings].
    Nasrallah HA; Rivera-Calimlin L; Rogol AD
    Psychopharmacol Bull; 1978 Jul; 14(3):46-7. PubMed ID: 353871
    [No Abstract]   [Full Text] [Related]  

  • 53. Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
    Siris SG; Adan F; Lee A; Cooper TB; Mandeli J; Casey E
    J Clin Psychiatry; 1988 Feb; 49(2):64-5. PubMed ID: 3338977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
    Van Putten T; Aravagiri M; Marder SR; Wirshing WC; Mintz J; Chabert N
    Psychopharmacol Bull; 1991; 27(2):91-6. PubMed ID: 1924666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacokinetics of the depot antipsychotics.
    Jann MW; Ereshefsky L; Saklad SR
    Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with coulometric detection.
    Luo JP; Hubbard JW; Midha KK
    J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(2):303-8. PubMed ID: 9061468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
    McLaren S; Cookson JC; Silverstone T
    Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
    Steiner S; Nagy C
    Int Pharmacopsychiatry; 1981; 16(3):184-92. PubMed ID: 7319750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
    Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
    Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.